Latest Bapineuzumab Stories
After another failed high-profile clinical trial, pharmaceutical companies Pfiizer Inc and Johnson & Johnson have said they’ve halted research and development of bapineuzumab.
An international team of scientists led by researchers at Mount Sinai School Medicine have discovered that a drug that had previously yielded conflicting results in clinical trials for Alzheimer's disease effectively stopped the progression of memory deterioration and brain pathology in mouse models of early stage Alzheimer's disease.
In one of two late-stage trials conducted by Pfizer, an experimental Alzheimer’s drug failed to slow the disease’s progress, but the pharma said on Monday that it will continue to study the drug’s effect on the other group.
Immunotherapy with the antibody bapineuzumab in patients with mild to moderate Alzheimer disease resulted in decreases in a cerebrospinal fluid biomarker, which may indicate downstream effects on the degenerative process.